IGF-1 DES
high riskAlso: IGF-1 DES(1-3) · Truncated IGF-1 · Des-IGF-1
IGF-1 DES is a truncated form of IGF-1 lacking the first 3 amino acids of the N-terminus. Has approximately 10x greater potency than standard IGF-1 at the receptor but does not bind IGF binding proteins — limiting systemic distribution. Used for localized muscle hypertrophy by injection at target sites.
Reported Benefits
Local muscle hypertrophy
Animal and in vitro data show localized anabolic effects; human controlled data absent.
Mechanism of Action
Truncated IGF-1 lacking N-terminal tripeptide; does not bind IGFBPs → primarily local receptor activation; more potent receptor binding than intact IGF-1; activates local mTOR/satellite cell pathways.
Local vs. Systemic: The Distinction
Unlike IGF-1 LR3 (systemic distribution), IGF-1 DES’s lack of binding protein affinity means it acts primarily at the injection site. This is the basis for its localized hypertrophy claims. The evidence for this claimed specificity in humans is largely preclinical.
Regulatory Status
Research OnlySafety Profile
Side Effects
- •Local tissue overgrowth
- •Hypoglycemia (less than LR3)
- •WADA-prohibited
- •Injection site complications
Contraindications
- •Active malignancy
- •Cancer history
Drug Interactions
- •Insulin
Primary Uses
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe IGF-1 DES?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →